A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Non-interventional Observational Study to Evaluate the Baseline FSH, Ovarian Volume and AFC (Antral Follicle Count) as Prognostic Factors of the Outcome of the In-vitro Fertilization/Intracytosolic Sperm Injection (IVF/ICSI) in Infertile Patients Who Receive r-FSH (GONAL-f®) for Controlled Ovarian Hyperstimulation|
- Live birth rate [ Time Frame: Up to 28 days after birth ]
- Pregnancy rate (ongoing, clinical, biochemical) [ Time Frame: up to 40 weeks post embryo-transfer ]Biochemical: up to 2 weeks post embryo-transfer / clinical: up to 12 weeks post embryo-transfer / ongoing: up to 40 weeks post embryo-transfer
- Fertilization rate [ Time Frame: 24 hours post oocyte retrieval ]
- Implantation rate [ Time Frame: 2 weeks post embryo-transfer ]
- Detailed record of adverse events [ Time Frame: Up to 1 year after subject enrollment ]
- Hormone (E2) levels on hCG day [ Time Frame: Up to 12 hours prior to hCG administration ]
- Duration of treatment [ Time Frame: Up to 12 hours post last FSH injection ]
- Total amount of FSH administered [ Time Frame: Up to 1 hour post last FSH injection ]
- Number of oocytes [ Time Frame: Up to 1 hour post oocyte retrieval ]
- Miscarriage rate [ Time Frame: Up to 12 weeks post embryo-transfer ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||October 2008|
|Study Completion Date:||January 2011|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
Treatment of subfertility and infertility by assisted reproduction technologies (ART) such as IVF and embryo transfer (ET) requires multiple follicular development to increase the number of female gametes, and the chances of a successful treatment outcome. These technologies include the stimulation of multiple follicular development by exogenous FSH administration and the suppression of endogenous luteinizing hormone (LH) secretion by administration of a GnRH analogue (antagonist or agonist, as required). A single dose of human chorionic gonadotropin (hCG) is administered to mimic the endogenous LH surge and induce final oocyte maturation after adequate follicular development. Recombinant-hFSH (r-hFSH) has been shown to be efficacious in terms of number of oocytes recovered and in terms of pregnancy rates as compared to urinary-hFSH.
Gonal-f fill-by-mass is available as a liquid formulation that can be administered with the pen device. The pen device is prefilled and hence the subject does not require to assemble the device making it simpler to use. The prefilled pen allows the accurate delivery of a precise dose of r-hFSH in 37.5 International Units (IU) increments.
- Evaluation of the significance of baseline FSH, ovarian volume and AFC with a model adjusted for age as prognostic factors of the IVF/ICSI treatment outcome.
This study planned to enrol 500 female subjects undergoing COH for IVF/ICSI-treatment with Gonal-f. Gonal-f will be administered daily subcutaneously (s.c.) according to the centre's usual clinical practice, commencing on Days 2 or 3 of the cycle during the stimulation period. Treatment with Gonal-f will be continued until adequate follicular development has been achieved with the dose adjusted according to the subject's response, to usually not higher than 450 IU daily. A single injection of 250 micrograms r-hCG or 5,000 IU up to 10,000 IU hCG would be administered 24-48 hours after the last Gonal-f injection to induce final follicular maturation. Gonal-f will be started approximately 2 weeks after the start of an gonadotrophin-releasing hormone (GnRH) agonist treatment, both being continued until adequate follicular development will be achieved. Oocyte retrieval will be done 34-36 hours after hCG administration followed by IVF/ICSI treatment according to clinic's protocol. Each enrolled subject would be followed up until the confirmation of her pregnancy status. Active follow up of all pregnancies will be performed, including those subjects withdrawn from the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01196143
|Centre of Assisted Reproduction "Embryoland"|
|Athens, Greece, 11 523|
|Study Director:||Michalis Arvanitis, MD, MSc||Merck A.E. Hellas,Greece, an affiliate of MerckKGaA, Darmstadt, Germany|